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Abstract: Patients with end-stage renal disease (ESRD), whether on conservative, 
peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood 
lymphocytes and an increased cancer incidence, especially of the kidney. The damage is 
possibly due to accumulation of uremic toxins like advanced glycation endproducts or 
homocysteine. However, other endogenous substances with genotoxic properties, which are 
increased in ESRD, could be involved, such as the blood pressure regulating hormones 
angiotensin II and aldosterone or the inflammatory cytokine TNF-. This review provides 
an overview of genomic damage observed in ESRD patients, focuses on possible 
underlying causes and shows modulations of the damage by modern dialysis strategies and 
vitamin supplementation. 
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1. Introduction 
In the United States of America, 13.1% of the population over 20 years were estimated to be 
suffering from chronic kidney disease in 2004, and in 2007, 0.18% received renal replacement therapy 
([1] and United States Renal Data System, www.usrds.org). An approximate 45% increase in 
prevalence is expected in 2020 due to the increasing age of the population (United States Renal Data 
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System, www.usrds.org). Similar values have been observed in other industrialized nations. Thus, an 
increasing number of people will receive renal replacement therapy for lengthier periods of time. 
Besides causing cardiovascular and other complications, end-stage renal disease (ESRD) is further 
characterized by a high incidence of cancer [2–4]. Of the cancer types recorded in these 
epidemiological studies, the risk of kidney cancer is tremendously increased. Depending on the 
continent, it is three- to ten-times higher than that seen in the control population [2]. 
Several biological parameters of ESRD patients were measured to determine their burden of 
genomic damage. Structural DNA damage, like single and double strand breaks and alkali labile sites, 
detectable with one of the standard genotoxicity assays, the comet assay, was significantly increased in 
lymphocytes of patients under dialysis [5–7]. These types of DNA damage are theoretically repairable. 
Yet, DNA repair capacity is reduced by prolonged hemodialysis therapy [8]. Unrepaired or improperly 
repaired DNA lesions may have serious consequences, such as premature ageing [9,10], 
atherosclerosis [11] and cancer predisposition [12]. 
Furthermore, unrepairable genomic damage per se, such as sister chromatid exchanges and 
chromosome breaks, were found in lymphocytes of dialysis patients [13–15]. In addition to the DNA 
in the nucleus, the mitochondrial DNA was also shown to be affected: deletions and mutations were 
observed in mitochondrial DNA of muscle cells and in the easily accessible hair follicles [16–18]. 
Furthermore, the most prominent oxidative DNA lesion, the modified base 7,8-dihydro-8-oxo-guanine 
(8-oxodG), is increased in ESRD [19]. 8-oxodG has a high mutagenic potential and repair errors or 
unrepaired 8-oxodGs lead to G:C→T:A transversions, which are often found in genes altered in 
tumors [20]. 
In this review, the impact of different dialysis therapies and of supplementation with vitamins on 
genomic damage of dialysis patients will be discussed. Also, underlying mechanisms of the origin of 
the increased DNA damage in ESRD will be described. 
2. Causes of Increased Genomic Damage in ESRD 
2.1. Genotoxic Uremic Toxins 
Several minerals and molecules accumulate in the blood of patients with ESRD, which, if not 
removed, may lead to death. Besides urea, which is the classical uremic toxin, over 90 other toxins 
were included in the encyclopedic overview of uremic retention solutes initiated by the European 
Uremic Toxin Work Group (EUTox). These compounds, excreted by healthy kidneys under normal 
conditions, are classified as low molecular weight water-soluble compounds, middle molecules and 
protein-bound compounds [21]. In the seven years since the first review of EUTox, over 25 additional 
solutes have been identified ([22] and EUTox database: http://www.nephro-leipzig.de/eutoxdb/ 
viewtoxins.php). It is conceivable that not all compounds responsible for the uremic syndrome have 
yet been discovered. 
Genotoxic or mutagenic properties were reported for some of the toxins in the database,   
e.g., hydroquinone, indoxyl sulfate, leptin, methylglyoxal, N--(carboxymethyl)lysine and   
TNF- [6,23–26]. Other compounds, like trihalomethanes and heterocyclic amines, not included in the 
EUTox database but shown to accumulate in ESRD, are known mutagens [27,28]. These toxins, as Toxins 2010, 2  
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well as other, not yet recognized substances can contribute to the genomic damage in ESRD by 
directly causing DNA damage. 
2.2. Oxidative Stress 
Reactive oxygen species (ROS) perform important physiological functions, for example in immune 
defense or in cellular signal transduction. However, when present in high concentrations they damage 
cellular structures, including lipids, membranes, proteins and nucleic acids [29]. Oxidative damage to 
DNA comprises single and double strand breaks, DNA base modifications, abasic sites and DNA 
crosslinks. Cells can protect themselves against oxidative damage with antioxidants, antioxidative 
enzymes and repair of the lesions [30]. This balance between the formation of ROS and protective 
mechanisms can be destabilized in situations of excessive production of free radicals and/or of 
deficient antioxidant defense, resulting in oxidative stress. 
In kidney disease, oxidative stress is already found in the early stages, reflected by increased levels 
of various biomarkers of oxidative stress [31,32]. With decline of kidney function, the oxidative stress 
increases [33,34]. Different sources of oxidative stress in ESRD have been identified: (1) The dialysis 
procedure itself causes oxidative stress, with ROS being excreted by inflammatory cells on the surface 
of the dialysis membranes, which depletes scavenging molecules [35,36]; (2) Indeed, a significant 
reduction of the glutathione based scavenging system was observed in ESRD patients, in addition to 
lower levels of antioxidant enzymes such as superoxide dismutase, and a vitamin C-, as well as a 
vitamin E-deficiency [31,37–40]; (3) The dietary restriction necessary in ESRD, with a low intake of 
fresh fruits and vegetables, also plays a role in the vitamin deficiency; (4) Many factors accompanying 
ESRD, like malnutrition or chronic volume overload, lead to a permanent state of microinflammation, 
which further increases ROS formation by activated neutrophils [41]. 
3. Influence of Different Dialysis Therapies on Genomic Damage in ESRD 
Dialysis is applied to achieve the removal of toxic solutes and of fluid overload whereby the 
patient’s blood is in contact with dialysis fluid across a semi-permeable membrane. This membrane 
can be the natural peritoneal membrane in peritoneal dialysis or an artificial membrane in a 
hemodialysis filter used for extracorporeal dialysis. The driving force of the fluid and solute exchange 
is osmosis, hydrostatic pressure, and a concentration gradient leading to diffusion and convection [42]. 
Dialysis achieves a solute removal of approximately 10% of that of a healthy kidney and cannot 
replace the kidney’s endocrine functions. Therefore, dialysis patients are on a special diet and need 
supplementary medication. 
The most commonly used modalities in renal replacement therapy are peritoneal dialysis (PD) and 
hemodialysis (HD). Recent studies recommend peritoneal dialysis as an initial therapy, when 
applicable, to better preserve the important residual renal function and prolong overall   
survival [43,44]. The benefits of PD for survival are maintained up to the third year, after which 
survival with PD and HD is the same, or even slightly lower in patients on PD [45,46]. HD is 
conventionally delivered thrice weekly for four hours either in a dialysis center or at home. An 
improved uremic state can be obtained by shorter interdialytic intervals in daily HD, achieving an 
increased removal of small solutes and lower plasma concentrations of various uremic toxins [47–50]. Toxins 2010, 2  
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A further technique is hemodiafiltration (HDF), which combines the diffusion mechanism of HD with 
the convective component of hemofiltration. In this way, the clearance of both low and high molecular 
weight uremic toxins (up to 25 kDa) is improved [51,52]. 
3.1. Hemodialysis—Hemodiafiltration 
A meta-analysis of 20 studies totaling 657 patients comparing convective dialysis strategies with 
conventional HD did not find significant differences in mortality, number of hospital admissions per 
year or dialysis adequacy. Due to the small number of patients included in the individual studies and 
the overall suboptimal quality of these studies, the convective modalities could not be evaluated 
definitively [53]. Not included in this analysis were the results of the large European Dialysis 
Outcomes and Practice Pattern Study (DOPPS), which found that patients receiving high efficiency 
HDF had a 35% lower mortality risk than those receiving low-flux HD [54]. Studies comparing HD 
and HDF observed a better clearance of middle molecules such as 2 microglobulin, leptin or 
complement factor D [55,56], but even small molecules like urea and phosphate were better removed 
by HDF [57]. This more effective removal of uremic compounds seems to be essential for the reduction 
of the mortality risk, since the beneficial effect persisted even after statistical adjustment for dialysis 
efficiency (Kt/V) [58]. 
HDF also had a more beneficial influence on oxidative stress parameters than did HD. Total 
antioxidant capacity and glutathione peroxidase activity were increased and reactive oxygen 
metabolites, including pentosidine, advanced oxidation protein products (AOPPs) and oxidized LDL, 
were decreased in patients undergoing HDF compared to HD [59–62]. In addition, the p22phox 
subunit of NADPH oxidase—one of the enzymes possibly partly responsible for the increased 
oxidative stress—was found to be less expressed in patients on HDF compared to patients on HD [62]. 
Last, but not least, the amount of the oxidative 8-oxodG base modification, quantified in lymphocytes 
after a dialysis session, was significantly lower in HDF than in HD [60], supporting the hypothesis that 
the HDF procedure is superior not only in eliminating molecules generating oxidative stress or 
produced by oxidative stress, but itself causes less oxidative stress than HD [63]. 
The fact that HDF better removes middle molecules, and decreases oxidative stress and also 
inflammation, as shown by lower C reactive protein (CRP) values of the patients [59,61], led to the 
assumption that patients on HDF might also show lower DNA damage. Results obtained from the 
comparison of the two different treatments are conflicting. One study, totaling 26 patients in the HD 
and 15 patients in the HDF group, did not show a difference in the DNA damage quantified with the 
comet assay [7]. In contrast, a yet unpublished study with 10 matched pairs of HD and HDF patients 
revealed less DNA damage measured by comet assay as well as a significant reduction of micronuclei 
in the HDF group patients (Table 1). Seven patients, who underwent a change of therapy from HD to 
HDF and were observed for a further eight months on HDF revealed a significant amelioration of 
DNA damage, as detected by comet assay, but no change in micronuclei frequency, which could be 
due to the rather long lifespan of lymphocytes [64]. Encompassing the observations of   
Vaslaki et al. [61], who found an improvement of many oxidative stress and inflammation parameters 
after switching HD patients to HDF for three months, HDF indeed might be more beneficial, Toxins 2010, 2  
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concerning oxidative and genomic damage, than HD. To prove this, further studies have to be 
conducted analyzing these parameters. 
Table 1. Patient characteristics, selected plasma parameters and markers of genotoxicity of 
matched patients on hemodialysis (red) and hemodiafiltration (blue). HD: hemodialysis; 
HDF: hemodiafiltration; CRP: C reactive protein; MN: micronuclei; BN: binucleated cells; 
CA: comet assay; 1–10: patient numbers. Methods used to obtain these data are explained 
in [64]. * p < 0.001 vs. HD; 
+ p = 0.074; paired t-test (SPSS 18). 
 Age 
Time on 
dialysis 
Creatinine CRP Urea HDF-MN  HDF-CA 
  (years)  (months)  (mg/dL)  (mg/dL) (mg/dL) (MN/1000 BN) (% DNA in tail)
HD1 64  53 14,95  0,38  189  19,0  18,8 
HDF1 62  50 12,79  0,77  171  17,7  16,1 
HD2 72  59 12,65  0,18  218  20,0  18,8 
HDF2 66  50 13,35  0,29  139  16,3  15,4 
HD3 68  28 12,76  0,30  179  18,3  14,2 
HDF3 66  36  9,33  0,56  129  16,3  13,8 
HD4 65  88 14,27  0,93  231  18,3  15,9 
HDF4 62  102 10,98  0,12  151  16,0  13,3 
HD5 43  78 13,56  0,79  194  21,3  15,6 
HDF5 45  69 14,48  0,29  220  17,7  12,9 
HD6 41  15 9,69  0,78  169  18,0  14,4 
HDF6 37  28 12,71  0,28  219  16,7  12,6 
HD7 48  155  14,72  0,13  219  21,0  17,3 
HDF7 51  158 11,26  0,46  192  16,0  13,3 
HD8 37  108  11,65  0,93  179  20,7  18,5 
HDF8 33  96 14,28  0,44  153  18,3  15,4 
HD9 59  167 7,97  0,24  143  18,7  17,7 
HDF9 60  162 8,41  0,27  134  15,0  16,1 
HD10 62  36 11,68  0,52  200  24,0  19,5 
HDF10 61  36  12,76  0,65  133  19,3  14,4 
mean HD  55.9 ± 11.9  78.4 ± 49.3  12.3 ± 2.2 0.5 ± 0.3 163 ± 35 19.9 ± 1.8  17.1 ± 1.8 
mean HDF  54.3 ± 11.5  78.7 ± 46.9  11.5 ± 2.3 0.4 ± 0.2 147 ± 23 
+ 16.9 ± 1.2 *  14.3 ± 1.3 * 
3.2. Hemodialysis—Daily Dialysis 
Another possibility for improving dialysis therapy is to increase the time or the frequency of HD. 
The necessity to test such modalities has arisen out of the realization that no significant improvement 
of survival has been achieved despite technical advances in dialysis [65]. Survival of patients 
undergoing dialysis at one, two and five years of follow-up is 86%, 75% and 49%, respectively. 
Observations from the early 1980s, when Charra et al. treated patients for eight hours thrice weekly 
with slow flow HD and found increased survival, suggested that a dialysis session with longer duration 
could be more physiological and also beneficial for the patient [66,67]. Three different techniques are 
currently used. Short daily hemodialysis (SDHD) consists typically of 2–3.5 hours, six to seven times Toxins 2010, 2  
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a week, long intermittent hemodialysis (LIHD) lasts 6–8 hours, three times a week, and nocturnal 
home hemodialysis (NHHD) is carried out overnight for 6–8 hours, five to seven times a week. All 
these dialysis modalities were studied mostly in small trials, resulting in the observation of 
improvements in a variety of clinical aspects and of the patients’ quality of life perception [68,69]. 
Additionally, a reduction in mortality between 17 to 78% was reported, as well as an increase of life 
expectancy of 9–15 years [70,71]. 
A recently published meta-analysis of 17 clinical studies analyzing the clinical effectiveness of 
SDHD identified possible reasons for the better outcome of patients receiving the daily treatment [72]. 
The clearest effect reported was the improvement of blood pressure control, resulting in a reduction of 
antihypertensive medication [47,73–77]. This is most probably achieved by a reduction of extracellular 
fluid excess, a lower interdialytic volume and a better control of sodium balance [72]. Erythropoetin 
treatment was also reduced in many patients under SDHD, explained by a better nutritional status as 
well as a removal of erythropoesis inhibiting uremic toxins [78,79]. Moreover, a better clearance of 
other uremic compounds was observed: of phosphorus [48,74,80–82], urea [47,48,73,74,77,82], 
homocysteine [83] and advanced glycation endproducts (AGEs, explained in detail below) [84]. 
Another beneficial aspect could be reduced inflammation as proven by lower levels of the 
inflammatory markers IL-6, TNF- and CRP in SDHD patients compared to standard HD [81,85,86]. 
A cross-sectional study comparing patients on SDHD and standard HD therapy with regard to 
genomic damage, markers of microinflammation and removal of AGEs, could not detect differences in 
the inflammatory state [87]. Nevertheless, genomic damage assessed with the micronucleus frequency 
test was significantly lower under SDHD, even approaching values of the healthy control group. An 
explanation for this could be the better removal of uremic toxins in SDHD patients. In the same study, 
the improved clearance of members of the AGE group was shown, which exhibited genotoxic potential 
in vitro [24]. 
4. Effects of Vitamin Supplementation on Genomic Damage in ESRD 
ESRD patients often suffer from vitamin deficiency of small water-soluble vitamins, such as 
vitamin C, due to a high rate of removal by dialysis and a restricted dietary intake. On the other hand, 
large fat-soluble vitamins, e.g., vitamin A, may be retained in the body [88]. Further reasons for the 
vitamin derangements in ESRD are drug interactions, which mostly affect the activity of folic acid, 
vitamin B6 and B12 [89]. Supplementation with vitamins in HD is therefore primarily used to 
compensate the deficiency. In addition, the distinct mechanisms of how the respective vitamins can 
ameliorate the state of health of the ESRD patients have been studied. Although the majority of 
investigations were conducted with supplementation of vitamin D and C, this review will now focus on 
studies analyzing the potential protective effects of vitamin supplementation against genomic damage 
in ESRD, employing vitamin E, B1, B12 and folic acid. 
4.1. Vitamin E 
While studies treating oxidative stress and inflammation with oral vitamin E produced conflicting 
results, the outcome of the four studies in dialysis patients concentrating on the effect of vitamin E 
supplementation on DNA damage unanimously show beneficial effects, which most probably can be Toxins 2010, 2  
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ascribed to the antioxidative actions of vitamin E. Independent of the type of administration, oral or 
per vitamin E-coated dialyser membrane, DNA damage was observed to decrease [5,19,90,91]. In the 
two studies in which patients were given vitamin E orally, DNA damage was assessed by comet assay 
in one and by quantifying 8-oxodG by HPLC in the other [5,19], thereby measuring both unspecific 
structural DNA damage and a specific oxidative base modification. The same holds true for the two 
studies analyzing the impact of vitamin E-coated membranes, one applying the comet assay and the 
other quantifying 8-oxodG [90,91]. The latter study also included a crossover design, where patients 
changed the dialyser membrane type from standard cellulose to vitamin E-coated cellulose and 
vice versa. In those patients changing to the vitamin E-coated membrane, the 8-oxodG levels in 
leukocyte DNA significantly fell by 41% after only eight weeks, while it rose in the other group  
by 66% [91]. An increasing number of studies employing vitamin E-coated dialysers report favorable 
effects on markers of inflammation and oxidative stress, but also on blood pressure [92–94]. One 
advantage of the vitamin E-coated dialyser membrane is that the vitamin E can execute its free radical 
scavenging activity directly when the blood first contacts the dialyser, without activation of the 
inflammatory response by the membrane in the first place. Additionally, a consumption of endogenous 
vitamin E is prevented [91]. New vitamin E-coated dialysers based on polysulfone are being tested, 
which will probably be even more biocompatible than the ones coated with cellulose [92]. 
4.2. Vitamin B1 
Beside oxidative stress generated by the activated immune cells, the formation of ROS can also be 
initiated by some uremic toxins, e.g., AGEs, which are a heterogeneous class of molecules formed by 
non-enzymatic reactions between reducing sugars and free amino groups of proteins, peptides, amino 
acids, lipids and also nucleic acids [95]. Best characterized are the protein modifications, including  
N--(carboxymethyl)lysine, pentosidine and methylglyoxal-derived hydroimidazolone. The resulting 
adducts cannot be degraded and accumulate on long-living proteins. They are characterized by brown 
color, fluorescence and a tendency to polymerize. Features of the AGE-cross-linked proteins include a 
decreased solubility and a high resistance to proteolysis, changing the biomechanical and biochemical 
properties of the affected tissues [96]. AGE formation is a normal process in ageing [97]. However, in 
some diseases AGEs accumulate, for example in diabetes mellitus due to elevated plasma glucose 
levels. In ESRD, AGE accumulation results from impaired renal removal, disturbed metabolism and 
higher oxidative stress [98–100]. AGE accumulation is associated with the development of 
complications of diabetes (nephropathy, retinopathy and neuropathy [101]) and ESRD (dialysis-related 
amyloidosis, bone resorption and atherosclerosis [102–104]). These deleterious effects are mediated in 
part by the modified proteins, but also by AGE-specific receptors. The most studied receptor of AGEs, 
RAGE, is a multi-ligand receptor of the immunoglobulin superfamily, a signal transducing receptor 
modulating cellular functions [105]. Binding of AGEs to RAGE leads to oxidative stress via the 
induction of NADPH oxidase and to activation of proinflammatory molecules, among them NF-B, 
which initiates increased expression of RAGE itself and starts a vicious circle [106,107]. These 
adverse effects of AGEs, together with their significantly increased plasma levels in ESRD, fulfill the 
criteria of uremic toxins: these compounds were classified as protein-bound uremic toxins [21]. Toxins 2010, 2  
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Vitamin B1 (thiamine), in the form of the lipid-soluble thiamine precursor benfotiamine, was shown 
to inhibit the formation of AGEs [108]. Thiamine is required for the normal function of heart, muscle 
and nerves. It plays a key role in cellular energy metabolism, converting carbohydrates to   
energy [109], as the co-factor of the enzyme transketolase, which converts glyceraldehyde-3-phosphate 
and fructose-6-phosphate to intermediates of the pentose phosphate pathway [110]. Supplementation 
with benfotiamine in diabetic patients demonstrated a significant relief in neuropathic pain and a 
marked improvement in vibration perception thresholds [111]. Vitamin B1 has been shown to be 
decreased in many diabetic patients due to enhanced urinary excretion and malabsorption [111]. This 
deficiency manifests itself in reduced transketolase activities compared to healthy subjects [112]. Low 
transketolase is connected to neuropathies observed in approximately 25% of uremic patients and 
probably contributes to the unexplained cases of encephalopathy in the dialysis population [113–115]. 
Strikingly, although thiamine deficiency in dialysis patients was already observed in the early   
1980s [116] and the hypothesis of a role of transketolase deficiency in uremic neuropathy exists since 
the 1970s [113], to date no clinical studies have analyzed the effect of thiamine supplementation on 
neurological problems in dialysis patients. By contrast, first clinical trials of thiamine in diabetic 
patients with neuropathies were conducted as early as 1992 and reported improvement of the 
symptoms [117]. Pharmacokinetic studies in dialysis patients were carried out, revealing the 
superiority of the bioavailability of benfotiamine versus thiamine [118]. 
Benfotiamine, therefore, was used in the first studies analyzing the impact of vitamin B1 
supplementation on genomic damage of HD patients [119]. In two small consecutive prospective 
studies totaling 30 treated patients, the administration of 450–600 mg per day of benfotiamine for four 
months successfully decreased the micronucleus frequency of peripheral lymphocytes. The number of 
micronuclei was inversely correlated to the erythrocyte transketolase activity. Surprisingly, no effect 
of benfotiamine on plasma content of fluorescent AGEs could be detected. Since an intrinsic 
antioxidative capacity of benfotiamine unrelated to its anti-AGE effects was observed in vitro as well 
as in vivo [120,121], and the antioxidative plasma capacity of the benfotiamine-treated patients 
increased, the reduction of genomic damage can be explained with this property of benfotiamine. 
Possibly longer observation periods in humans are needed to reliably detect a lowering of 
plasma AGEs. 
4.3. Folic Acid in Combination with Vitamin B12 
Another uremic toxin whose formation can probably be influenced by supplementation with 
vitamins is homocysteine. Hyperhomocysteinemia was detected in approximately 85% of ESRD 
patients and persists throughout dialysis and even after renal transplantation [122]. Homocysteine is a 
normal intermediate in methionine metabolism, usually recycled to methionine with the involvement 
of folic acid and vitamin B12 [123]. Methionine is used for protein synthesis and, after conversion to  
S-adenosylmethionine, is an important methyl donor for transmethylation reactions, needed for example 
for DNA cytosine-methylation. Inhibition of DNA methyltransferases by S-adenosylhomocysteine was 
observed in individuals with increased homocysteine plasma levels, accompanied by hypomethylated 
DNA [124]. Insufficient DNA methylation renders the DNA less stable [125], possibly leading to Toxins 2010, 2  
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genomic damage. Indeed, a correlation between plasma homocysteine levels and the number of 
micronuclei was found in humans [126]. 
Clinical studies analyzing the efficacy of folic acid alone or in combination with vitamin B12 
(sometimes further combined with vitamin B6) on homocysteine levels in dialysis patients report 
inconsistent results. The plasma level of homocysteine was reduced markedly in only a few of the 
recently conducted trials [127,128], while there were only small changes in others [129,130]. The 
primary outcomes of the larger studies, all-cause mortality, cardiovascular events or cognitive 
function, were not ameliorated at all by the vitamin supplementations [127,131–133]. 
To date, the only study to explore the effect of supplementation with folic acid and vitamin B12 on 
genomic damage in dialysis patients observed a significant decline in plasma homocysteine levels, but 
no corresponding changes in the percentage of DNA methylation [134]. Nevertheless, genomic 
damage, assessed as micronucleus frequency, decreased in a therapy-length dependent manner. A 
possible antioxidant capacity of the supplemented vitamins could account for this beneficial effect. 
5. Further Uremic Toxins with Genotoxic Properties 
Apart from the above described uremic toxins with genotoxic effects, advanced glycation 
endproducts and homocysteine, further substances classified as uremic toxins show DNA damaging 
effects (Table 2). This was confirmed primarily by the comet assay, but also by detection of 
chromosome breaks and formation of the oxidative base modification 8-oxodG. It can be assumed that 
these molecules contribute to the increased genomic damage observed in dialysis patients. Since the 
uremic syndrome is characterized by accumulation of multiple compounds, synergistic actions of these 
compounds, amplifying their genotoxic potential, cannot be ruled out. Identification of additional 
uremic toxins and intensified research uncovering their toxicological properties will lead to an 
expansion of Table 2. 
Table 2. Examples of uremic toxins [21,22], with published evidence of DNA-damaging potential. 
Uremic toxin  DNA damage  References 
Angiotensin II   8-oxodG, micronuclei, double strand breaks, abasic sites  [135,136] 
Hydroquinone  DNA strand breaks, micronuclei, 8-oxodG  [137] 
Indoxyl sulfate  DNA strand breaks  [120] 
Leptin  DNA strand breaks  [6] 
Methylglyoxal  DNA strand breaks, 8-oxodG  [24,138] 
N--(carboxymethyl)lysine  DNA strand breaks  [24] 
N-methyl-2-pyridone-5-carboxamide  DNA strand breaks  [139] 
Nitrosodimethylamine  DNA strand breaks, micronuclei, known  
rat-liver carcinogen 
[140–142] 
Thiocyanate  DNA strand breaks  [143] 
TNF-  8-oxodG, DNA strand breaks  [25,144] 
 Toxins 2010, 2  
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6. Conclusions 
The possible modulation of genomic damage in ESRD by more intensive HD techniques more 
effectively removing uremic toxins and by supplementation with substances counteracting adverse 
effects of uremic toxins further supports the presumption that these compounds are mainly responsible 
for the formation of the DNA damage. The ability of a uremic toxin to induce the generation of 
oxidative stress seems to be a prerequisite for the formation of DNA damage. In addition to improving 
the overall condition of dialysis patients, HD techniques ensuring a more effective removal of uremic 
toxins, could also reduce the accumulation of genomic damage, possibly preventing the complication 
“malignancy” in dialysis patients. 
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